Spago Nanomedical AB (XSAT:SPAG BTA) EPS (Basic): kr0.00 (TTM As of Mar. 2026)


What is Spago Nanomedical AB EPS (Basic)?

Spago Nanomedical AB XSAT:SPAG BTA 30 EPS (Basic) is kr0.00 as of Mar. 2026. GuruFocus rates XSAT:SPAG BTA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Spago Nanomedical AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00.

Spago Nanomedical AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00.

Spago Nanomedical AB's EPS without NRI for the three months ended in Mar. 2026 was kr0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 44.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 35.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 17.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Spago Nanomedical AB's highest 3-Year average EPS without NRI Growth Rate was 47.60% per year. The lowest was -14.20% per year. And the median was 13.60% per year.

Spago Nanomedical AB  (XSAT:SPAG BTA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Spago Nanomedical AB EPS (Basic) Related Terms

Spago Nanomedical AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Spago Nanomedical AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spago Nanomedical AB EPS (Basic) Chart

Spago Nanomedical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spago Nanomedical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spago Nanomedical AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Spago Nanomedical AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-26.554-0)/3.606
=-7.36

Spago Nanomedical AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-6.798-0)/3.606
=-1.89

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr0.00 mean?
Spago Nanomedical AB (XSAT:SPAG BTA) has a EPS (Basic) of kr0.00 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Spago Nanomedical AB and its competitors.
Is Spago Nanomedical AB's EPS (Basic) too high?
Spago Nanomedical AB's current EPS (Basic) is kr0.00. Overall, Spago Nanomedical AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's EPS (Basic) compare to VRTX and REGN?
Spago Nanomedical AB's EPS (Basic) of kr0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current EPS (Basic) is kr0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Spago Nanomedical AB (XSAT:SPAG BTA) has a current EPS (Basic) of kr0.00. The current EPS (Basic) is kr0.00. Spago Nanomedical AB's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Spago Nanomedical AB (XSAT:SPAG BTA), the current EPS (Basic) is kr0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spago Nanomedical AB Business Description

Other Exchanges SPAGO:Sweden
Address Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.